<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2016.5027</article-id>
<article-id pub-id-type="publisher-id">or-36-04-2094</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Casticin induces DNA damage and inhibits DNA repair-associated protein expression in B16F10 mouse melanoma cancer cells</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Shih</surname><given-names>Yung-Luen</given-names></name><xref rid="af1-or-36-04-2094" ref-type="aff">1</xref><xref rid="af2-or-36-04-2094" ref-type="aff">2</xref><xref rid="af3-or-36-04-2094" ref-type="aff">3</xref><xref rid="fn1-or-36-04-2094" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chou</surname><given-names>Jason</given-names></name><xref rid="af4-or-36-04-2094" ref-type="aff">4</xref><xref rid="fn1-or-36-04-2094" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>Yeh</surname><given-names>Ming-Yang</given-names></name><xref rid="af5-or-36-04-2094" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chou</surname><given-names>Hsiao-Min</given-names></name><xref rid="af1-or-36-04-2094" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chou</surname><given-names>Hsiu-Chen</given-names></name><xref rid="af1-or-36-04-2094" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Lu</surname><given-names>Hsu-Feng</given-names></name><xref rid="af6-or-36-04-2094" ref-type="aff">6</xref><xref rid="af7-or-36-04-2094" ref-type="aff">7</xref></contrib>
<contrib contrib-type="author">
<name><surname>Shang</surname><given-names>Hung-Sheng</given-names></name><xref rid="af8-or-36-04-2094" ref-type="aff">8</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chueh</surname><given-names>Fu-Shin</given-names></name><xref rid="af9-or-36-04-2094" ref-type="aff">9</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chu</surname><given-names>Yung-Lin</given-names></name><xref rid="af10-or-36-04-2094" ref-type="aff">10</xref></contrib>
<contrib contrib-type="author">
<name><surname>Hsueh</surname><given-names>Shu-Ching</given-names></name><xref rid="af7-or-36-04-2094" ref-type="aff">7</xref><xref rid="af11-or-36-04-2094" ref-type="aff">11</xref><xref ref-type="corresp" rid="c2-or-36-04-2094"/></contrib>
<contrib contrib-type="author">
<name><surname>Chung</surname><given-names>Jing-Gung</given-names></name><xref rid="af12-or-36-04-2094" ref-type="aff">12</xref><xref rid="af13-or-36-04-2094" ref-type="aff">13</xref><xref ref-type="corresp" rid="c1-or-36-04-2094"/></contrib></contrib-group>
<aff id="af1-or-36-04-2094">
<label>1</label>Department of Pathology and Laboratory Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan</aff>
<aff id="af2-or-36-04-2094">
<label>2</label>School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, Taiwan</aff>
<aff id="af3-or-36-04-2094">
<label>3</label>School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan</aff>
<aff id="af4-or-36-04-2094">
<label>4</label>Department of Pathology, Cheng-Hsin General Hospital, Taipei, Taiwan</aff>
<aff id="af5-or-36-04-2094">
<label>5</label>Office of Director, Cheng-Hsin General Hospital, Taipei, Taiwan</aff>
<aff id="af6-or-36-04-2094">
<label>6</label>Department of Restaurant, Hotel and Institutional Management, Fu-Jen Catholic University, New Taipei, Taiwan</aff>
<aff id="af7-or-36-04-2094">
<label>7</label>Department of Clinical Pathology, Cheng-Hsin General Hospital, Taipei, Taiwan</aff>
<aff id="af8-or-36-04-2094">
<label>8</label>Department of Pathology, National Defense Medical Center, Division of Clinical Pathology, Tri-Service General Hospital, Taipei, Taiwan</aff>
<aff id="af9-or-36-04-2094">
<label>9</label>Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan</aff>
<aff id="af10-or-36-04-2094">
<label>10</label>International Master's Degree Program in Food Science, International College, National Pingtung University of Science and Technology, Pingtung, Taiwan</aff>
<aff id="af11-or-36-04-2094">
<label>11</label>Division of Hematology and Oncology, Cheng-Hsin General Hospital, Taipei, Taiwan</aff>
<aff id="af12-or-36-04-2094">
<label>12</label>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan</aff>
<aff id="af13-or-36-04-2094">
<label>13</label>Department of Biotechnology, Asia University, Taichung, Taiwan, R.O.C.</aff>
<author-notes>
<corresp id="c1-or-36-04-2094">Correspondence to: Professor Jing-Gung Chung, Department of Biological Science and Technology, China Medical University. 91 Hsueh-Shih Road, Taichung 404, Taiwan, R.O.C., E-mail: <email>jgchung@mail.cmu.edu.tw</email></corresp>
<corresp id="c2-or-36-04-2094">Dr Shu-Ching Hsueh, Division of Hematology and Oncology, Cheng-Hsin General Hospital, 45 Cheng Hsin Street, Pai-Tou, Taipei 112, Taiwan, R.O.C., E-mail: <email>ch1835@chgh.org.tw</email></corresp><fn id="fn1-or-36-04-2094">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>08</month>
<year>2016</year></pub-date>
<volume>36</volume>
<issue>4</issue>
<fpage>2094</fpage>
<lpage>2100</lpage>
<history>
<date date-type="received">
<day>01</day>
<month>02</month>
<year>2016</year></date>
<date date-type="accepted">
<day>09</day>
<month>03</month>
<year>2016</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016, Spandidos Publications</copyright-statement>
<copyright-year>2016</copyright-year></permissions>
<abstract>
<p>Casticin, a polymethoxyflavone, has been demonstrated to possess anticancer activities, yet no study has shown in detail that casticin induces DNA damage in lung cancer cells. The purpose of this study was to investigate the possible molecular mechanisms of casticin which induce DNA damage and nuclear condensation in murine melanoma cancer B16F10 cells. In this study, by examining and capturing images using phase contrast microscopy, we found that casticin induced cell morphological changes. Moreover, it decreased the total number of viable cells which was measured by flow cytometry. Casticin-induced DNA damage and nuclear DNA condensation were measured by DAPI staining, respectively. Western blotting indicated that casticin decreased the protein levels of <italic>O<sup>6</sup></italic>-methylguanine-DNA methyltransferase (MGMT), breast cancer 1, early onset (BRCA1), mediator of DNA damage checkpoint 1 (MDC1), DNA-dependent protein kinase (DNA-PK) but increased phospho-p53 tumor suppressor protein (p-p53), phospho-ataxia telangiectasia mutated kinase (p-ATM), phospho-histone H2A.X (Ser139) and poly(ADP-ribose) polymerase (PARP) in the B16F10 cells. Furthermore, we used confocal laser system microscopy to examine the protein expression levels and we found that casticin increased the expression of p-p53 and p-H2A.X in the B16F10 cells. Collectively, casticin induced DNA damage and affected DNA repair proteins in the B16F10 cells <italic>in vitro</italic>.</p></abstract>
<kwd-group>
<kwd>casticin</kwd>
<kwd>DNA condensation</kwd>
<kwd>DAPI staining</kwd>
<kwd>murine melanoma B16F10 cells</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>It is well known that anti-neoplastic drugs interfere with the structure and functions of DNA directly or indirectly. However, they sometimes not only affect target cells but also normal cells. In light of this, comprehension of the anticancer functions still require investigation in order to reduce the side effects before their use in the direct treatment of patients. Thus, there is not only the need to evaluate the impairment caused by anticancer drugs on the whole organism but also to investigate the effects of genotoxic alterations at a cellular level (<xref rid="b1-or-36-04-2094" ref-type="bibr">1</xref>). Currently, numerous compounds from natural plants have been shown to induce cell death via the induction of cell apoptosis. However, the interruption of cell DNA damage is also needed because these effects can lead to cell death. Some anticancer drugs such as cisplatin or etoposide have been shown to induce DNA damage and eventually cell death (<xref rid="b2-or-36-04-2094" ref-type="bibr">2</xref>). Thus, focusing on the ability of these compounds to interfere with DNA and produce DNA damage will be helpful and critical to understand how these compounds induce cell death.</p>
<p>Casticin, one of the ingredients derived from <italic>Fructus viticis</italic> (<xref rid="b3-or-36-04-2094" ref-type="bibr">3</xref>), has been shown to exhibit anticancer activity in prostate (<xref rid="b4-or-36-04-2094" ref-type="bibr">4</xref>), breast (<xref rid="b5-or-36-04-2094" ref-type="bibr">5</xref>), colon (<xref rid="b6-or-36-04-2094" ref-type="bibr">6</xref>,<xref rid="b7-or-36-04-2094" ref-type="bibr">7</xref>), lung (<xref rid="b8-or-36-04-2094" ref-type="bibr">8</xref>,<xref rid="b9-or-36-04-2094" ref-type="bibr">9</xref>), cervical (<xref rid="b10-or-36-04-2094" ref-type="bibr">10</xref>), gastric (<xref rid="b11-or-36-04-2094" ref-type="bibr">11</xref>) and ovarian cancer (<xref rid="b12-or-36-04-2094" ref-type="bibr">12</xref>), glioma (<xref rid="b13-or-36-04-2094" ref-type="bibr">13</xref>) and leukemia (<xref rid="b14-or-36-04-2094" ref-type="bibr">14</xref>) Recently it was reported that forkhead box O3 (FOXO3a) is a critical mediator of the inhibitory effects of casticin on apoptosis in breast cancer cells (<xref rid="b3-or-36-04-2094" ref-type="bibr">3</xref>). Furthermore, casticin significantly induced cell apoptosis through the activation of the apoptosis signal-regulating kinase 1-c-Jun N-terminal kinase (ASK1-JNK)-Bim signaling cascade and the accumulation of reactive oxygen species (ROS) in colon cancer cells (<xref rid="b15-or-36-04-2094" ref-type="bibr">15</xref>). However, there is no available information to show that casticin induces cell apoptosis in melanoma cancer cells. Furthermore, there is no report showing that casticin induces DNA damage and affects DNA repair-associated protein expression levels in melanoma cells.</p>
<p>After melanoma becomes metastatic melanoma, it is characterized by a high mortality rate (<xref rid="b16-or-36-04-2094" ref-type="bibr">16</xref>) due to a universal resistance to standard chemotherapy (<xref rid="b17-or-36-04-2094" ref-type="bibr">17</xref>). Hence, the motality rate from unresectable melanoma continues to rise (<xref rid="b18-or-36-04-2094" ref-type="bibr">18</xref>). Presently, the ineffectiveness of the treatments available, encourage additional studies to identify novel therapeutic molecules, delivery systems, and/or combination therapies for the treatment of melanoma (<xref rid="b19-or-36-04-2094" ref-type="bibr">19</xref>). Casticin may be a potential antitumor agent with both antitumor and anti-proliferative activities. However, the effects of casticin on DNA damage and repair with associated protein expression are not widely known. Thus, the objective of this study was to investigate DNA damage and repair of melanoma B16F10 cells and our results confirmed that casticin induced DNA damage and affected DNA repair systems <italic>in vitro</italic>.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Chemicals and reagents</title>
<p>Casticin, dimethyl sulfoxide (DMSO), propidium iodide (PI), Trypsin-EDTA, penicillin-streptomycin, anti-MGMT (cat no. M3068), anti-PARP (cat no. P248), anti-p-ATMSer1981 (cat no. SBA4300100) and anti-&#x003B2;-actin (cat no. A5316) were all purchased from Sigma Chemical Co. (St. Louis, MO, USA). Anti-DNA-PK (cat no. PC127) was purchased from Calbiochem (San Diego, CA, USA). Anti-p-H2A.X (cat no. GTX80694) and anti-BRCA1 (cat no. GTX70111), were purchased from GeneTex Inc. (Irvine, CA, USA). Anti-p-p53 (cat no. sc-7997) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-MDC1 (cat no. 05-1572) was purchased from Millipore (Billerica, MA, USA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco<sup>&#x000AE;</sup>/Invitrogen Life Technologies (Carlsbad, CA, USA).</p></sec>
<sec>
<title>Cell culture</title>
<p>The murine melanoma cell line (B16F10) was purchased from the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cells were grown in 75-cm<sup>2</sup> flasks with DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 <italic>&#x000B5;</italic>g/ml streptomycin at 37&#x000B0;C in 5% CO<sub>2</sub> humidified incubators (<xref rid="b20-or-36-04-2094" ref-type="bibr">20</xref>).</p></sec>
<sec>
<title>Cellular morphology and viability examination</title>
<p>B16F10 cells were plated at a density of 1&#x000D7;10<sup>5</sup> cells/well into 12-well plates in DMEM. After the required confluency was reached, cells were exposed to 0, 20, 30 and 40 <italic>&#x000B5;</italic>M of casticin for 24 and 48 h in a 5% CO<sub>2</sub> incubator at 37&#x000B0;C. Cells were examined and their images were captured by contrast phase microscopy at &#x000D7;200 magnification. Subsequently, the cells were collected, washed and stained with PI (5 <italic>&#x000B5;</italic>g/ml) in phosphate-buffered saline (PBS) and were analyzed by flow cytometry (Becton-Dickinson, San Jose, CA, USA) for the total percentage of viable cells as previously described (<xref rid="b21-or-36-04-2094" ref-type="bibr">21</xref>).</p></sec>
<sec>
<title>4&#x02032;,6-Diamidino-2-phenylindole dihydrochloride (DAPI) staining for DNA condensation examination</title>
<p>B16F10 cells (1.5&#x000D7;10<sup>5</sup> cells/well) were plated onto a 6-well plate for 24 h and then were exposed to casticin (30 <italic>&#x000B5;</italic>M) for 0, 6, 24 and 48 h. After treatment, 4% formaldehyde in PBS was used to fix cells for 10 min and then DAPI staining followed. After staining, the cells were examined and their images were captured using a fluorescence microscope at &#x000D7;200 magnification as previously described (<xref rid="b21-or-36-04-2094" ref-type="bibr">21</xref>).</p></sec>
<sec>
<title>Western blotting for examination of protein expression</title>
<p>B16F10 cells (1&#x000D7;10<sup>6</sup> cells/dish) were plated onto a 10-cm dish and were incubated with 30 <italic>&#x000B5;</italic>M of casticin for 0, 6, 24 and 48 h. Cells were collected, suspended in sodium dodecyl sulfate (SDS) sample buffer, sonicated, boiled for 10 min as previously described (<xref rid="b21-or-36-04-2094" ref-type="bibr">21</xref>) and were centrifuged at 12,000 rpm for 15 min. The supernatant was collected and the concentrations of the total protein were determined by Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The cells were electro-phoresed by 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). Immune complexes were formed by incubation of proteins with primary antibodies (anti-MGMT, anti-BRCA1, anti-PARP, anti-p-p53, anti-MDC1, anti-DNA-PK, anti-p-ATM and anti-&#x003B2;-actin) at 4&#x000B0;C (overnight) followed by incubation with a secondary antibody. Immunoreactive protein bands were visualized with a chemiluminescent detection system and the protein expression levels were measured as described by the manufacturer (<xref rid="b20-or-36-04-2094" ref-type="bibr">20</xref>,<xref rid="b21-or-36-04-2094" ref-type="bibr">21</xref>).</p></sec>
<sec>
<title>Confocal laser microscopy for examination of protein translocation</title>
<p>B16F10 cells were plated at a density of 1.5&#x000D7;10<sup>5</sup> cells/well on a 6-well plate and were treated with 30 <italic>&#x000B5;</italic>M of casticin for 48 h. After treatment, cells were fixed in 4% formaldehyde in PBS for 15 min and 0.1% Triton X-100 in PBS was added to permeable cells. Subsequently, cells were washed with PBS and blocked with 1% BSA in PBS for 60 min and then they were stained with primary anti-p-p53 and anti-p-H2A.X (green fluorescence) overnight followed by staining with a secondary antibody (FITC-conjugated goat anti-mouse IgG). After being washed, cells were stained using PI (red fluorescence) for nuclei. All samples were mounted and photomicrographed by using a Leica TCS SP2 confocal spectral microscope (Leica Microsystems, Heidelberg, Mannheim, Germany) as previously described (<xref rid="b21-or-36-04-2094" ref-type="bibr">21</xref>).</p></sec>
<sec>
<title>Statistical analysis</title>
<p>The comparisons between the casticintreated and the untreated groups were performed using the Student's t-test, to determine the statistical significance of the differences between these groups. P&lt;0.05 was considered to be significant.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Casticin induces cell morphology and decreases the total viability of the B16F10 cells</title>
<p>B16F10 cells were treated with various concentrations of casticin (0, 20, 30 and 40 <italic>&#x000B5;</italic>M) at 24 and 48 h. Cells were examined for morphological changes and images were captured using a phase contrast microscope at &#x000D7;200 magnification (<xref rid="f1-or-36-04-2094" ref-type="fig">Fig. 1</xref>). The results indicated that casticin induced cell morphological changes in a dose-dependent manner. Cells were collected in order to measure the percentage of viable cells by flow cytometric assay (<xref rid="f2-or-36-04-2094" ref-type="fig">Fig. 2</xref>). The results indicated that the percentage of total cell viability was decreased significantly after treatment with casticin and that this effect was dose-dependent. The treatment of casticin at 48 h had a higher effect than that at 24 h.</p></sec>
<sec>
<title>Casticin induces nuclear DNA condensation of B16F10 cells</title>
<p>In order to further confirm whether casticin induced cell death via nuclear DNA condensation in the B16F10 cells, we selected 30 <italic>&#x000B5;</italic>M of casticin for treatment with cells at 0, 6, 24 and 48 h, Subsequently the cells were stained with DAPI to examine the formation of DNA condensation (<xref rid="f3-or-36-04-2094" ref-type="fig">Fig. 3A and B</xref>). The results indicated that casticin induced nuclear DNA condensation in the B16F10 cells and this effect was time-dependent.</p></sec>
<sec>
<title>Casticin affects DNA damage of the associated proteins in the B16F10 cells</title>
<p>Cells were treated with 30 <italic>&#x000B5;</italic>M of casticin for 0, 6, 24 and 48 h and then DNA damage of the associated proteins such as <italic>O</italic><sup>6</sup>-methylguanine-DNA methyltransferase (MGMT), p-H2A.X, breast cancer 1 and early onset (BRCA1), poly(ADP-ribose) polymerase (PARP), phospho-p53 tumor suppressor protein (p-p53), mediator of DNA damage checkpoint 1 (MDC1), DNA-dependent protein kinase (DNA-PK) and phospho-ataxia telangiectasia mutated kinase (p-ATM) were examined by western blot analysis (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4</xref>). The results indicated that casticin decreased the protein levels of MGMT and BRCA1 (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4A</xref>) and MDC1 (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>), but increased the levels of p-H2A.X and PARP (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4A</xref>), p-p53 and p-ATM (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>) in the B16F10 cells. These effects are associated with DNA damage and repair that may lead to cell death.</p></sec>
<sec>
<title>Casticin affects the translocation of p-p53 and p-H2A.X in the B16F10 cells</title>
<p>To further confirm whether casticin affects DNA damage in associated protein translocation in the B16F10 cells, cells were treated with 30 <italic>&#x000B5;</italic>M of casticin and then they were examined by confocal microscopy (<xref rid="f5-or-36-04-2094" ref-type="fig">Fig. 5</xref>). The results revealed that casticin increased the p-p53 (<xref rid="f5-or-36-04-2094" ref-type="fig">Fig. 5A</xref>) and p-H2A.X (<xref rid="f5-or-36-04-2094" ref-type="fig">Fig. 5B</xref>) expression levels in the cytoplasm when compared to the control groups and these observations indicate that casticin induces DNA damage and repair and may also regulate p-p53 and p-H2A.X in the cytoplasm in the B16F10 cells.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Based on the review of the literature, casticin was found to induce cell death (cytotoxic effects) via both induction of cell cycle arrest and apoptosis in many types of human cancer cells, but there is no available information showing that casticin induces DNA damage and repair and affects associated protein expression in human cancer cells. Therefore, in the present study, we investigated the cytotoxic effects of casticin and whether, through the induction of DNA damage, it affected DNA repair and associated protein expression levels in mouse melanoma B16F10 cells <italic>in vitro</italic>. After B16F10 cells were exposed to various concentrations of casticin we found that i) casticin induced cell morphological changes (<xref rid="f1-or-36-04-2094" ref-type="fig">Fig. 1</xref>) and decreased the total cell viability (percentage of viable cells) in a concentration- and time-dependent manner (<xref rid="f2-or-36-04-2094" ref-type="fig">Fig. 2</xref>); ii) a time-dependent increase in nuclear DNA condensation was observed in the B16F10 cells after exposure to casticin, which was assayed by DAPI staining (<xref rid="f3-or-36-04-2094" ref-type="fig">Fig. 3</xref>); iii) casticin decreased the proteins levels of MGMT and BRCA1 (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4A</xref>), and MDC1 (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>), and increased the levels of p-H2A.X and PARP (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4A</xref>), p-p53 and p-ATM (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>) in the B16F10 cells and these effects were time-dependent; iv) casticin induced DNA damage and repair and may also regulate p-p53 (<xref rid="f5-or-36-04-2094" ref-type="fig">Fig. 5A</xref>) and p-H2A.X (<xref rid="f5-or-36-04-2094" ref-type="fig">Fig. 5B</xref>) which are increased in the cytoplasm when compared to the control groups in the B16F10 cells.</p>
<p>We observed that casticin induced cell morphological changes and decreased the total percentage of viable B16F010 cells in a dose-dependent manner at 20&#x02013;40 <italic>&#x000B5;</italic>M. Thus, we further examined whether casticin induced cell death and was associated with induction of DNA damage in the B16F10 cells. Based on the results from <xref rid="f3-or-36-04-2094" ref-type="fig">Fig. 3</xref>, it was revealed that casticin induced DNA damage and condensation in the B16F10 cells which were assayed by DAPI staining, respectively. It has been reported that specific and bulky DNA lesions which trigger cell apoptosis have been identified (<xref rid="b22-or-36-04-2094" ref-type="bibr">22</xref>). It has been well documented that DAPI staining can reveal DNA fragmentation and nuclear DNA condensation and our results indicated that casticin induced nuclear DNA condensation in a time-dependent manner. Recently, a new type of anti-neoplastic therapy has emerged, whose aim is to manipulate DNA damage response (DDR) (<xref rid="b23-or-36-04-2094" ref-type="bibr">23</xref>&#x02013;<xref rid="b25-or-36-04-2094" ref-type="bibr">25</xref>) as DDR inhibition has been proven as an effective treatment for cancer. It has been reported that oxidative DNA damage has been recognized to be an etiological factor in aging and in the development of systemic diseases including cancer in the human population (<xref rid="b26-or-36-04-2094" ref-type="bibr">26</xref>,<xref rid="b27-or-36-04-2094" ref-type="bibr">27</xref>). In cells, DNA repair enzymes monitor chromosomes and correct damaged nucleotides to prevent these adverse effects (<xref rid="b28-or-36-04-2094" ref-type="bibr">28</xref>).</p>
<p>In the present study, our findings are the first to provide information regarding casticin-induced DNA damage and the affect on the DNA repair system in the B16F10 cells (<xref rid="f3-or-36-04-2094" ref-type="fig">Fig. 3</xref>). Western blotting (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4</xref>) indicated that casticin induced DNA damage and affected repair in associated protein expression levels such as MGMT and BRCA1 (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4A</xref>), MDC1 and DNA-PK (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>) but increased the levels of p-H2A.X and PARP (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4A</xref>) and p-p53 and p-ATM (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>) in the B16F10 cells. It has been reported that MGMT is a DNA repair enzyme which eliminates <italic>O</italic><sup>6</sup> methylguanines (<xref rid="b29-or-36-04-2094" ref-type="bibr">29</xref>) and that the inhibition of MGMT may be strategic in increasing tumor susceptibility to chemotherapy (<xref rid="b30-or-36-04-2094" ref-type="bibr">30</xref>). In breast and ovarian cancers, BRCA1 plays an important role in DNA repair in the maintainance of genomic stability (<xref rid="b31-or-36-04-2094" ref-type="bibr">31</xref>) and in breast cancer, BRCA1 promoter methylation was found to be positively associated with increased mortality (<xref rid="b32-or-36-04-2094" ref-type="bibr">32</xref>). MDC1 and BRCA1 represent important assets in the repair of double-strand breaks after DNA damage occurs (<xref rid="b33-or-36-04-2094" ref-type="bibr">33</xref>,<xref rid="b34-or-36-04-2094" ref-type="bibr">34</xref>). Furthermore, MDC1 may affect the radiosensitivity of tumor cells (<xref rid="b35-or-36-04-2094" ref-type="bibr">35</xref>). It has been reported that DNA-PK is a serine/threonine protein kinase and is expressed in most mammalian cells (<xref rid="b36-or-36-04-2094" ref-type="bibr">36</xref>). DNA-PK plays an important role in the main repair pathway of DNA double-strand breaks and cells deficient in DNA-PK exhibit hypersensitivity to radio/chemotherapy (<xref rid="b37-or-36-04-2094" ref-type="bibr">37</xref>&#x02013;<xref rid="b39-or-36-04-2094" ref-type="bibr">39</xref>). It has also been reported that anticancer drugs such as 5-FU induce DNA double-strand breaks, and the presence of p-H2A.X which is a phosphorylated form of the histone H2A.X which has been shown to be a specific marker for the detection of these DNA breaks was observed (<xref rid="b40-or-36-04-2094" ref-type="bibr">40</xref>). Based on this observation, we suggest that casticin induced double-strand breaks in the B16F10 cells.</p>
<p>Moreover, it has been reported that the ATM/p53 pathway is involved in the apoptosis of various cancer cells induced by chemotherapy drugs (<xref rid="b41-or-36-04-2094" ref-type="bibr">41</xref>). Herein, results from the western blot analysis indicated that casticin increased the protein levels of proteins p-p53 and p-ATM (<xref rid="f4-or-36-04-2094" ref-type="fig">Fig. 4B</xref>) in the B16F10 cells which was also confirmed by confocal laser system microscopy examination (<xref rid="f5-or-36-04-2094" ref-type="fig">Fig. 5</xref>). Notably, it has also been reported that antioxidant <italic>N</italic>-acetylcysteine (NAC) pretreatment enhances ATM and p53 phosphorylation, p53 acetylation and H2A.X phosphorylation in ovarian cancer cells (<xref rid="b42-or-36-04-2094" ref-type="bibr">42</xref>). In view of this, the possible signaling pathways involved in the casticin-induced DNA damage and nuclear condensation in the B16F10 cells are summarized in <xref rid="f6-or-36-04-2094" ref-type="fig">Fig. 6</xref>. Thus, further studies should be conducted to elucidate the exact molecular mechanism of casticin-induced DNA damage and how to affect DNA damage and repair-associated signaling pathways.</p></sec></body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was supported by grant CMU103-ASIA-01 from China Medical University (Taichung, Taiwan) and by grant 103-08 and 103-41 from Cheng Hsin General Hospital (Taipei, Taiwan). Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research and Development at China Medical University (Taichung, Taiwan).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-36-04-2094"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrella</surname><given-names>A</given-names></name><name><surname>Lavorgna</surname><given-names>M</given-names></name><name><surname>Criscuolo</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>C</given-names></name><name><surname>Isidori</surname><given-names>M</given-names></name></person-group><article-title>Ecogenotoxicity of six anticancer drugs using comet assay in daphnids</article-title><source>J Hazard Mater</source><volume>286</volume><fpage>573</fpage><lpage>580</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.jhazmat.2015.01.012</pub-id><pub-id pub-id-type="pmid">25638790</pub-id></element-citation></ref>
<ref id="b2-or-36-04-2094"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Bo</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63</article-title><source>Tumour Biol</source><volume>36</volume><fpage>9365</fpage><lpage>9372</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s13277-015-3642-5</pub-id><pub-id pub-id-type="pmid">26108997</pub-id></element-citation></ref>
<ref id="b3-or-36-04-2094"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LP</given-names></name><name><surname>Cao</surname><given-names>XC</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Quan</surname><given-names>MF</given-names></name><name><surname>Sheng</surname><given-names>XF</given-names></name><name><surname>Ren</surname><given-names>KQ</given-names></name></person-group><article-title>Casticin induces breast cancer cell apoptosis by inhibiting the expression of forkhead box protein M1</article-title><source>Oncol Lett</source><volume>7</volume><fpage>1711</fpage><lpage>1717</lpage><year>2014</year><pub-id pub-id-type="pmid">24765206</pub-id><pub-id pub-id-type="pmcid">3997681</pub-id></element-citation></ref>
<ref id="b4-or-36-04-2094"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisskopf</surname><given-names>M</given-names></name><name><surname>Schaffner</surname><given-names>W</given-names></name><name><surname>Jundt</surname><given-names>G</given-names></name><name><surname>Sulser</surname><given-names>T</given-names></name><name><surname>Wyler</surname><given-names>S</given-names></name><name><surname>Tullberg-Reinert</surname><given-names>H</given-names></name></person-group><article-title>A Vitex agnus-castus extract inhibits cell growth and induces apoptosis in prostate epithelial cell lines</article-title><source>Planta Med</source><volume>71</volume><fpage>910</fpage><lpage>916</lpage><year>2005</year><pub-id pub-id-type="doi">10.1055/s-2005-871235</pub-id><pub-id pub-id-type="pmid">16254821</pub-id></element-citation></ref>
<ref id="b5-or-36-04-2094"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha&#x000EF;dara</surname><given-names>K</given-names></name><name><surname>Zamir</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>QW</given-names></name><name><surname>Batist</surname><given-names>G</given-names></name></person-group><article-title>The flavonoid casticin has multiple mechanisms of tumor cytotoxicity action</article-title><source>Cancer Lett</source><volume>242</volume><fpage>180</fpage><lpage>190</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.canlet.2005.11.017</pub-id><pub-id pub-id-type="pmid">16387422</pub-id></element-citation></ref>
<ref id="b6-or-36-04-2094"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>H</given-names></name><name><surname>Denda</surname><given-names>T</given-names></name><name><surname>Ohyama</surname><given-names>K</given-names></name><name><surname>Hirobe</surname><given-names>C</given-names></name><name><surname>Toyoda</surname><given-names>H</given-names></name></person-group><article-title>Cytotoxic effects of flavonoids against a human colon cancer derived cell line, COLO 201: A potential natural anti-cancer substance</article-title><source>Cancer Lett</source><volume>276</volume><fpage>74</fpage><lpage>80</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.canlet.2008.10.036</pub-id></element-citation></ref>
<ref id="b7-or-36-04-2094"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>SY</given-names></name><name><surname>Zhong</surname><given-names>MZ</given-names></name><name><surname>Yuan</surname><given-names>GJ</given-names></name><name><surname>Hou</surname><given-names>SP</given-names></name><name><surname>Yin</surname><given-names>LL</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>ZY</given-names></name></person-group><article-title>Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells</article-title><source>Oncol Rep</source><volume>29</volume><fpage>474</fpage><lpage>480</lpage><year>2013</year></element-citation></ref>
<ref id="b8-or-36-04-2094"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>DJ</given-names></name><name><surname>Ahn</surname><given-names>HS</given-names></name><name><surname>Chung</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>DG</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>M</given-names></name><name><surname>Bae</surname><given-names>H</given-names></name></person-group><article-title>Inhibitory effects of casticin on migration of eosinophil and expression of chemokines and adhesion molecules in A549 lung epithelial cells via NF-&#x003BA;B inactivation</article-title><source>J Ethnopharmacol</source><volume>136</volume><fpage>399</fpage><lpage>405</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.jep.2011.01.014</pub-id><pub-id pub-id-type="pmid">21251967</pub-id></element-citation></ref>
<ref id="b9-or-36-04-2094"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>QQ</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>MW</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>NQ</given-names></name><name><surname>Long</surname><given-names>LZ</given-names></name><name><surname>Quan</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregu-lation of DR5 in human lung cancer cells</article-title><source>Asian Pac J Trop Med</source><volume>6</volume><fpage>372</fpage><lpage>378</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/S1995-7645(13)60041-3</pub-id><pub-id pub-id-type="pmid">23608376</pub-id></element-citation></ref>
<ref id="b10-or-36-04-2094"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name></person-group><article-title>Induction of apoptosis by casticin in cervical cancer cells: Reactive oxygen species-dependent sustained activation of Jun N-terminal kinase</article-title><source>Acta Biochim Biophys Sin (Shanghai)</source><volume>44</volume><fpage>442</fpage><lpage>449</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/abbs/gms013</pub-id></element-citation></ref>
<ref id="b11-or-36-04-2094"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Long</surname><given-names>L</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name></person-group><article-title>Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress</article-title><source>PLoS One</source><volume>8</volume><fpage>e58855</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0058855</pub-id><pub-id pub-id-type="pmid">23536831</pub-id><pub-id pub-id-type="pmcid">3594187</pub-id></element-citation></ref>
<ref id="b12-or-36-04-2094"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>XC</given-names></name><name><surname>Cao</surname><given-names>JG</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Quan</surname><given-names>MF</given-names></name><name><surname>Sheng</surname><given-names>XF</given-names></name><name><surname>Ren</surname><given-names>KQ</given-names></name></person-group><article-title>Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a</article-title><source>Oncol Lett</source><volume>5</volume><fpage>1605</fpage><lpage>1610</lpage><year>2013</year><pub-id pub-id-type="pmid">23761826</pub-id><pub-id pub-id-type="pmcid">3678892</pub-id></element-citation></ref>
<ref id="b13-or-36-04-2094"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Casticin induces human glioma cell death through apoptosis and mitotic arrest</article-title><source>Cell Physiol Biochem</source><volume>31</volume><fpage>805</fpage><lpage>814</lpage><year>2013</year><pub-id pub-id-type="doi">10.1159/000350098</pub-id><pub-id pub-id-type="pmid">23816816</pub-id></element-citation></ref>
<ref id="b14-or-36-04-2094"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JK</given-names></name><name><surname>Du</surname><given-names>HP</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>YG</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><article-title>Casticin induces leukemic cell death through apoptosis and mitotic catastrophe</article-title><source>Ann Hematol</source><volume>88</volume><fpage>743</fpage><lpage>752</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s00277-008-0677-3</pub-id><pub-id pub-id-type="pmid">19139893</pub-id></element-citation></ref>
<ref id="b15-or-36-04-2094"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>FX</given-names></name><name><surname>Cao</surname><given-names>XC</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>KQ</given-names></name></person-group><article-title>Activation of the apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase pathway is involved in the casticin-induced apoptosis of colon cancer cells</article-title><source>Exp Ther Med</source><volume>8</volume><fpage>1494</fpage><lpage>1500</lpage><year>2014</year><pub-id pub-id-type="pmid">25289048</pub-id><pub-id pub-id-type="pmcid">4186484</pub-id></element-citation></ref>
<ref id="b16-or-36-04-2094"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Leiter</surname><given-names>U</given-names></name></person-group><article-title>Melanoma epidemiology and trends</article-title><source>Clin Dermatol</source><volume>27</volume><fpage>3</fpage><lpage>9</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.clindermatol.2008.09.001</pub-id></element-citation></ref>
<ref id="b17-or-36-04-2094"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jilaveanu</surname><given-names>LB</given-names></name><name><surname>Aziz</surname><given-names>SA</given-names></name><name><surname>Kluger</surname><given-names>HM</given-names></name></person-group><article-title>Chemotherapy and biologic therapies for melanoma: Do they work?</article-title><source>Clin Dermatol</source><volume>27</volume><fpage>614</fpage><lpage>625</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.clindermatol.2008.09.020</pub-id><pub-id pub-id-type="pmid">19880049</pub-id></element-citation></ref>
<ref id="b18-or-36-04-2094"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Naishadham</surname><given-names>D</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><volume>62</volume><fpage>10</fpage><lpage>29</lpage><year>2012</year><pub-id pub-id-type="doi">10.3322/caac.20138</pub-id><pub-id pub-id-type="pmid">22237781</pub-id></element-citation></ref>
<ref id="b19-or-36-04-2094"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lillehammer</surname><given-names>T</given-names></name><name><surname>Engesaeter</surname><given-names>BO</given-names></name><name><surname>Prasmickaite</surname><given-names>L</given-names></name><name><surname>Maelandsmo</surname><given-names>GM</given-names></name><name><surname>Fodstad</surname><given-names>O</given-names></name><name><surname>Engebraaten</surname><given-names>O</given-names></name></person-group><article-title>Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines</article-title><source>J Gene Med</source><volume>9</volume><fpage>440</fpage><lpage>451</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/jgm.1036</pub-id><pub-id pub-id-type="pmid">17410615</pub-id></element-citation></ref>
<ref id="b20-or-36-04-2094"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YM</given-names></name><name><surname>Velmurugan</surname><given-names>BK</given-names></name><name><surname>Kuo</surname><given-names>WW</given-names></name><name><surname>Chen</surname><given-names>YS</given-names></name><name><surname>Ho</surname><given-names>TJ</given-names></name><name><surname>Tsai</surname><given-names>CT</given-names></name><name><surname>Ye</surname><given-names>CX</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name></person-group><article-title>Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells</article-title><source>BioMedicine</source><volume>3</volume><fpage>148</fpage><lpage>152</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.biomed.2013.05.001</pub-id></element-citation></ref>
<ref id="b21-or-36-04-2094"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chueh</surname><given-names>FS</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>JS</given-names></name><name><surname>Hsueh</surname><given-names>SC</given-names></name><name><surname>Ji</surname><given-names>BC</given-names></name><name><surname>Lu</surname><given-names>HF</given-names></name><name><surname>Chung</surname><given-names>JG</given-names></name></person-group><article-title>Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes</article-title><source>Oncol Rep</source><volume>29</volume><fpage>613</fpage><lpage>618</lpage><year>2013</year></element-citation></ref>
<ref id="b22-or-36-04-2094"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname><given-names>WP</given-names></name><name><surname>Kaina</surname><given-names>B</given-names></name></person-group><article-title>DNA damage-induced cell death by apoptosis</article-title><source>Trends Mol Med</source><volume>12</volume><fpage>440</fpage><lpage>450</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.molmed.2006.07.007</pub-id><pub-id pub-id-type="pmid">16899408</pub-id></element-citation></ref>
<ref id="b23-or-36-04-2094"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>YC</given-names></name><name><surname>Weng</surname><given-names>HC</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Chien</surname><given-names>YW</given-names></name></person-group><article-title>Curcuminoids cellular uptake by human primary colon cancer cells as quantitated by a sensitive HPLC assay and its relation with the inhibition of proliferation and apoptosis</article-title><source>J Agric Food Chem</source><volume>55</volume><fpage>8213</fpage><lpage>8222</lpage><year>2007</year><pub-id pub-id-type="doi">10.1021/jf070684v</pub-id><pub-id pub-id-type="pmid">17760412</pub-id></element-citation></ref>
<ref id="b24-or-36-04-2094"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ireson</surname><given-names>C</given-names></name><name><surname>Orr</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name><name><surname>Verschoyle</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>CK</given-names></name><name><surname>Luo</surname><given-names>JL</given-names></name><name><surname>Howells</surname><given-names>L</given-names></name><name><surname>Plummer</surname><given-names>S</given-names></name><name><surname>Jukes</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production</article-title><source>Cancer Res</source><volume>61</volume><fpage>1058</fpage><lpage>1064</lpage><year>2001</year><pub-id pub-id-type="pmid">11221833</pub-id></element-citation></ref>
<ref id="b25-or-36-04-2094"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ireson</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name><name><surname>Orr</surname><given-names>S</given-names></name><name><surname>Coughtrie</surname><given-names>MW</given-names></name><name><surname>Boocock</surname><given-names>DJ</given-names></name><name><surname>Williams</surname><given-names>ML</given-names></name><name><surname>Farmer</surname><given-names>PB</given-names></name><name><surname>Steward</surname><given-names>WP</given-names></name><name><surname>Gescher</surname><given-names>AJ</given-names></name></person-group><article-title>Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>11</volume><fpage>105</fpage><lpage>111</lpage><year>2002</year><pub-id pub-id-type="pmid">11815407</pub-id></element-citation></ref>
<ref id="b26-or-36-04-2094"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname><given-names>MR</given-names></name><name><surname>Frei</surname><given-names>B</given-names></name></person-group><article-title>Can antioxidant vitamins materially reduce oxidative damage in humans?</article-title><source>Free Radic Biol Med</source><volume>26</volume><fpage>1034</fpage><lpage>1053</lpage><year>1999</year><pub-id pub-id-type="doi">10.1016/S0891-5849(98)00302-5</pub-id><pub-id pub-id-type="pmid">10232849</pub-id></element-citation></ref>
<ref id="b27-or-36-04-2094"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohia</surname><given-names>SE</given-names></name><name><surname>Opere</surname><given-names>CA</given-names></name><name><surname>Leday</surname><given-names>AM</given-names></name></person-group><article-title>Pharmacological consequences of oxidative stress in ocular tissues</article-title><source>Mutat Res</source><volume>579</volume><fpage>22</fpage><lpage>36</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2005.03.025</pub-id><pub-id pub-id-type="pmid">16055157</pub-id></element-citation></ref>
<ref id="b28-or-36-04-2094"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>RD</given-names></name><name><surname>Mitchell</surname><given-names>M</given-names></name><name><surname>Sgouros</surname><given-names>J</given-names></name><name><surname>Lindahl</surname><given-names>T</given-names></name></person-group><article-title>Human DNA repair genes</article-title><source>Science</source><volume>291</volume><fpage>1284</fpage><lpage>1289</lpage><year>2001</year><pub-id pub-id-type="doi">10.1126/science.1056154</pub-id><pub-id pub-id-type="pmid">11181991</pub-id></element-citation></ref>
<ref id="b29-or-36-04-2094"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christmann</surname><given-names>M</given-names></name><name><surname>Verbeek</surname><given-names>B</given-names></name><name><surname>Roos</surname><given-names>WP</given-names></name><name><surname>Kaina</surname><given-names>B</given-names></name></person-group><article-title>O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter meth-ylation and immunohistochemistry</article-title><source>Biochim Biophys Acta</source><volume>1816</volume><fpage>179</fpage><lpage>190</lpage><year>2011</year><pub-id pub-id-type="pmid">21745538</pub-id></element-citation></ref>
<ref id="b30-or-36-04-2094"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbeek</surname><given-names>B</given-names></name><name><surname>Southgate</surname><given-names>TD</given-names></name><name><surname>Gilham</surname><given-names>DE</given-names></name><name><surname>Margison</surname><given-names>GP</given-names></name></person-group><article-title>O<sup>6</sup>-Methylguanine-DNA methyltransferase inactivation and chemotherapy</article-title><source>Br Med Bull</source><volume>85</volume><fpage>17</fpage><lpage>33</lpage><year>2008</year><pub-id pub-id-type="doi">10.1093/bmb/ldm036</pub-id></element-citation></ref>
<ref id="b31-or-36-04-2094"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><article-title>Cancer susceptibility and the functions of BRCA1 and BRCA2</article-title><source>Cell</source><volume>108</volume><fpage>171</fpage><lpage>182</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00615-3</pub-id><pub-id pub-id-type="pmid">11832208</pub-id></element-citation></ref>
<ref id="b32-or-36-04-2094"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Gammon</surname><given-names>MD</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bestor</surname><given-names>TH</given-names></name><name><surname>Zeisel</surname><given-names>SH</given-names></name><name><surname>Wetmur</surname><given-names>JG</given-names></name><name><surname>Wallenstein</surname><given-names>S</given-names></name><name><surname>Bradshaw</surname><given-names>PT</given-names></name><name><surname>Garbowski</surname><given-names>G</given-names></name><name><surname>Teitelbaum</surname><given-names>SL</given-names></name><etal/></person-group><article-title>BRCA1 promoter methylation is associated with increased mortality among women with breast cancer</article-title><source>Breast Cancer Res Treat</source><volume>115</volume><fpage>397</fpage><lpage>404</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s10549-008-0075-5</pub-id><pub-id pub-id-type="pmcid">2693263</pub-id></element-citation></ref>
<ref id="b33-or-36-04-2094"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartkova</surname><given-names>J</given-names></name><name><surname>Horejs&#x000ED;</surname><given-names>Z</given-names></name><name><surname>Sehested</surname><given-names>M</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><name><surname>Rajpert-De Meyts</surname><given-names>E</given-names></name><name><surname>Skakkebaek</surname><given-names>NE</given-names></name><name><surname>Stucki</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name></person-group><article-title>DNA damage response mediators MDC1 and 53BP1: Constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours</article-title><source>Oncogene</source><volume>26</volume><fpage>7414</fpage><lpage>7422</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.onc.1210553</pub-id><pub-id pub-id-type="pmid">17546051</pub-id></element-citation></ref>
<ref id="b34-or-36-04-2094"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorgoulis</surname><given-names>VG</given-names></name><name><surname>Vassiliou</surname><given-names>LV</given-names></name><name><surname>Karakaidos</surname><given-names>P</given-names></name><name><surname>Zacharatos</surname><given-names>P</given-names></name><name><surname>Kotsinas</surname><given-names>A</given-names></name><name><surname>Liloglou</surname><given-names>T</given-names></name><name><surname>Venere</surname><given-names>M</given-names></name><name><surname>Ditullio</surname><given-names>RA</given-names><suffix>Jr</suffix></name><name><surname>Kastrinakis</surname><given-names>NG</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions</article-title><source>Nature</source><volume>434</volume><fpage>907</fpage><lpage>913</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/nature03485</pub-id><pub-id pub-id-type="pmid">15829965</pub-id></element-citation></ref>
<ref id="b35-or-36-04-2094"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gou</surname><given-names>Q</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>P</given-names></name></person-group><article-title>Downregulation of MDC1 and 53BP1 by short hairpin RNA enhances radiosensitivity in laryngeal carcinoma cells</article-title><source>Oncol Rep</source><volume>34</volume><fpage>251</fpage><lpage>257</lpage><year>2015</year><pub-id pub-id-type="pmid">25976740</pub-id></element-citation></ref>
<ref id="b36-or-36-04-2094"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><article-title>DNA-dependent protein kinase</article-title><source>Int J Biochem Cell Biol</source><volume>29</volume><fpage>935</fpage><lpage>938</lpage><year>1997</year><pub-id pub-id-type="doi">10.1016/S1357-2725(97)00006-X</pub-id><pub-id pub-id-type="pmid">9375373</pub-id></element-citation></ref>
<ref id="b37-or-36-04-2094"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belenkov</surname><given-names>AI</given-names></name><name><surname>Paiement</surname><given-names>JP</given-names></name><name><surname>Panasci</surname><given-names>LC</given-names></name><name><surname>Monia</surname><given-names>BP</given-names></name><name><surname>Chow</surname><given-names>TY</given-names></name></person-group><article-title>An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents</article-title><source>Cancer Res</source><volume>62</volume><fpage>5888</fpage><lpage>5896</lpage><year>2002</year><pub-id pub-id-type="pmid">12384553</pub-id></element-citation></ref>
<ref id="b38-or-36-04-2094"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>J</given-names></name><name><surname>Dziegielewski</surname><given-names>J</given-names></name><name><surname>Bolesta</surname><given-names>E</given-names></name><name><surname>Brautigan</surname><given-names>DL</given-names></name><name><surname>Larner</surname><given-names>JM</given-names></name></person-group><article-title>Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6</article-title><source>PLoS One</source><volume>4</volume><fpage>e4395</fpage><year>2009</year><pub-id pub-id-type="doi">10.1371/journal.pone.0004395</pub-id><pub-id pub-id-type="pmid">19198648</pub-id><pub-id pub-id-type="pmcid">2634843</pub-id></element-citation></ref>
<ref id="b39-or-36-04-2094"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shintani</surname><given-names>S</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Nakahara</surname><given-names>Y</given-names></name><name><surname>Hino</surname><given-names>S</given-names></name><name><surname>Nakashiro</surname><given-names>K</given-names></name><name><surname>Hamakawa</surname><given-names>H</given-names></name></person-group><article-title>Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma</article-title><source>Cancer Sci</source><volume>94</volume><fpage>894</fpage><lpage>900</lpage><year>2003</year><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01372.x</pub-id><pub-id pub-id-type="pmid">14556663</pub-id></element-citation></ref>
<ref id="b40-or-36-04-2094"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matuo</surname><given-names>R</given-names></name><name><surname>Sousa</surname><given-names>FG</given-names></name><name><surname>Escargueil</surname><given-names>AE</given-names></name><name><surname>Grivicich</surname><given-names>I</given-names></name><name><surname>Garcia-Santos</surname><given-names>D</given-names></name><name><surname>Chies</surname><given-names>JA</given-names></name><name><surname>Saffi</surname><given-names>J</given-names></name><name><surname>Larsen</surname><given-names>AK</given-names></name><name><surname>Henriques</surname><given-names>JA</given-names></name></person-group><article-title>5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line</article-title><source>J Appl Toxicol</source><volume>29</volume><fpage>308</fpage><lpage>316</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/jat.1411</pub-id></element-citation></ref>
<ref id="b41-or-36-04-2094"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000E4;&#x000E4;maa</surname><given-names>S</given-names></name><name><surname>Af H&#x000E4;llstr&#x000F6;m</surname><given-names>TM</given-names></name><name><surname>Sankila</surname><given-names>A</given-names></name><name><surname>Rantanen</surname><given-names>V</given-names></name><name><surname>Koistinen</surname><given-names>H</given-names></name><name><surname>Stenman</surname><given-names>UH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Taari</surname><given-names>K</given-names></name><etal/></person-group><article-title>DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue</article-title><source>Cancer Res</source><volume>70</volume><fpage>8630</fpage><lpage>8641</lpage><year>2010</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0937</pub-id><pub-id pub-id-type="pmid">20978201</pub-id></element-citation></ref>
<ref id="b42-or-36-04-2094"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brum</surname><given-names>G</given-names></name><name><surname>Carbone</surname><given-names>T</given-names></name><name><surname>Still</surname><given-names>E</given-names></name><name><surname>Correia</surname><given-names>V</given-names></name><name><surname>Szulak</surname><given-names>K</given-names></name><name><surname>Calianese</surname><given-names>D</given-names></name><name><surname>Best</surname><given-names>C</given-names></name><name><surname>Cammarata</surname><given-names>G</given-names></name><name><surname>Higgins</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>F</given-names></name><etal/></person-group><article-title>N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells</article-title><source>Int J Oncol</source><volume>42</volume><fpage>211</fpage><lpage>218</lpage><year>2013</year><pub-id pub-id-type="pmcid">3583638</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-36-04-2094" position="float">
<label>Figure 1</label>
<caption>
<p>Casticin induces cell morphological changes of viable mouse melanoma B16F10 cells. Cells (1&#x000D7;10<sup>5</sup> cells/well) were placed in 12-well plates and were treated with casticin (0, 20, 30 and 40 <italic>&#x000B5;</italic>M) for 48 h. Cells were examined and images were captured using phase contrast microscopy at &#x000D7;200 magnification.</p></caption>
<graphic xlink:href="OR-36-04-2094-g00.tif"/></fig>
<fig id="f2-or-36-04-2094" position="float">
<label>Figure 2</label>
<caption>
<p>Casticin decreases the percentage of viable mouse melanoma B16F10 cells. Cells (1&#x000D7;10<sup>5</sup> cells/well) were placed in 12-well plates and were treated with casticin (0, 20, 30 and 40 <italic>&#x000B5;</italic>M) for 24 (A) and 48 h (B). Cells were harvested and stained with PI (5 <italic>&#x000B5;</italic>g/ml) and analyzed by flow cytometry as described in 'Materials and methods'. <sup>&#x0002A;</sup>P&lt;0.05 indicates a significant difference between the casticin-treated and the untreated groups.</p></caption>
<graphic xlink:href="OR-36-04-2094-g01.tif"/></fig>
<fig id="f3-or-36-04-2094" position="float">
<label>Figure 3</label>
<caption>
<p>DAPI staining for nuclear DNA damage and condensation in the B16F10 cells. Cells (1.5&#x000D7;10<sup>5</sup> cells/well) were maintained in 6-well plates for 24 h and were treated with 30 <italic>&#x000B5;</italic>M of casticin for 0, 6, 24 and 48 h. Then the cells were stained with DAPI and were examined, and their images were captured using a fluorescence microscope at &#x000D7;200 magnification as described in 'Materials and methods'. (A) Representative images of DAPI staining; (B) mean of fluorescence (% of control). <sup>&#x0002A;</sup>P&lt;0.05 indicates a significant difference between the casticin-treated and the untreated groups.</p></caption>
<graphic xlink:href="OR-36-04-2094-g02.tif"/></fig>
<fig id="f4-or-36-04-2094" position="float">
<label>Figure 4</label>
<caption>
<p>Western blot analysis of protein levels of the proteins associated with DNA damage and repair in the B16F10 cells. Cells (1&#x000D7;10<sup>6</sup> cells/well) were placed in a 10-cm dish and then were incubated with 30 <italic>&#x000B5;</italic>M of cas-ticin for 0, 6, 24 and 48 h. The total amount of proteins was determined and the amounts of protein from each treatment were measured by SDS-PAGE and immunoblotting as described in 'Materials and methods'. (A) MGMT, p-H2A.X, BRCA1 and PARP. (B) p-p53, MDC1, DNA-PK and p-ATM.</p></caption>
<graphic xlink:href="OR-36-04-2094-g03.tif"/></fig>
<fig id="f5-or-36-04-2094" position="float">
<label>Figure 5</label>
<caption>
<p>Confocal laser system microscopy was used to examine the protein expression in the B16F10 cells. Cells (1.5&#x000D7;10<sup>5</sup> cells/well) were kept on a 6-well plate and were incubated with 30 <italic>&#x000B5;</italic>M of casticin for 48 h. Subsequently, they were fixed in 4% formaldehyde in PBS for 15 min followed by 0.1% Triton X-100 in PBS for 15 min. Immunostaining was then performed as described in 'Materials and methods'. (A) p-p53; (B) p-H2A.X. Both samples were examined and images were captured using a Leica TCS SP2 confocal spectral microscope.</p></caption>
<graphic xlink:href="OR-36-04-2094-g04.tif"/></fig>
<fig id="f6-or-36-04-2094" position="float">
<label>Figure 6</label>
<caption>
<p>The proposed signaling pathways involved in casticin-induced DNA damage and the effects on DNA repair proteins in the B16F10 cells.</p></caption>
<graphic xlink:href="OR-36-04-2094-g05.tif"/></fig></floats-group></article>
